Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
ACTIVE_NOT_RECRUITING
Status
Conditions
- Edema
- Erythema
- Estrogen Receptor Negative
- HER2/Neu Negative
- Peau d'Orange
- Progesterone Receptor Negative
- Recurrent Inflammatory Breast Carcinoma
- Stage IV Inflammatory Breast Carcinoma
- Triple-Negative Breast Carcinoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Pembrolizumab
Sponsor
M.D. Anderson Cancer Center
Collaborators